SCHEMBL10116367

SCHEMBL10116367

Cc1ccc(-c2ccc(NC(=O)c3ccc(NS(=O)(=O)C(C)(C)C)cc3)cc2)cc1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
MAPT P10636 6/20 0.52
MEN1 O00255 3/20 0.52
KDM4E B2RXH2 2/20 0.52
ALDH1A1 P00352 1/20 0.52
HTT P42858 1/20 0.52
LMNA P02545 2/20 0.48
PTGER4 P35408 1/20 0.47
TP53 P04637 1/20 0.46
MAPK14 Q16539 1/20 0.46
PTPN1 P18031 2/20 0.44
FKBP5 Q13451 1/20 0.44
THRB P10828 1/20 0.44
PSMD14 O00487 1/20 0.44
FGB P02675 1/20 0.44
POLB P06746 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10116298 0.87 NPC1 (0.61) KMT2ANPC1RAB9AMAPTMEN1
SCHEMBL10116240 0.85 MEN1 (0.55) KMT2ANPC1RAB9AMAPTMEN1
SCHEMBL10114523 0.84 MEN1 (0.60) KMT2AMAPTMEN1KDM4EHTT
SCHEMBL10116183 0.83 NPC1 (0.67) KMT2ANPC1RAB9AMAPTMEN1
SCHEMBL10116653 0.82 KMT2A (0.52) KMT2ANPC1RAB9AMAPTMEN1
SCHEMBL10116364 0.81 MAPT (0.53) KMT2ANPC1RAB9AMAPTMEN1
SCHEMBL10116182 0.80 KMT2A (0.57) KMT2ANPC1RAB9AMAPTMEN1
SCHEMBL10116194 0.80 MEN1 (0.65) KMT2ANPC1RAB9AMAPTMEN1
SCHEMBL10116238 0.80 KDM4E (0.65) KMT2ANPC1RAB9AMAPTMEN1
SCHEMBL10116416 0.79 HDAC1 (0.45) KMT2ANPC1RAB9AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R KMT2A 2912/4885NPC1 1435/4885RAB9A 3699/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R KMT2A 2768/4885NPC1 1353/4885RAB9A 3651/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R KMT2A 2953/4885NPC1 1462/4885RAB9A 3820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.